Shares of telemedicine company Teladoc Health (NYSE: TDOC) surprisingly popped on Thursday after Citron Research gave it a glowing recommendation. As of 3:30 p.m. ET, Teladoc stock was up 7%, but ...

Teladoc's shares recently jumped after Citron Research, an online investment newsletter, claimed the market is not fairly valuing the telehealth company given its increasing free cash flow ...

Teladoc Health (NYSE: TDOC) is scheduled to announce Q2 results on Tuesday, July 29th, after market close, and investor focus will be on the details behind usual numbers—especially segment trends, ...

Teladoc has consistently reported significant losses over the past years. As of Sept. 30, 2024, the company’s accumulated deficit reached $16.2 billion, up from $15.2 billion at the end of 2023.

Prominent short seller Andrew Left, the founder of Citron Research, has been charged by the U.S. Department of Justice with multiple counts of securities fraud for a $16 million stock market ...

Digital medical services platform Teladoc Health (NYSE:TDOC) reported Q2 CY2025 results , but sales fell by 1.6% year on year to $631.9 million. The company expects next quarter’s revenue to be around ...

Teladoc research shows AI-powered 'nudges' can improve diabetes members' engagement, health outcomes By Heather Landi Jun 24, 2024 8:10am ...

Live Updates Live Coverage Has Ended 'Under-the-Radar' AI Play 2:57 pm by Gerelyn Terzo Citron Research has come out touting Teladoc Health (Nasdaq: TDOC) as an “under-the-radar” AI stock ...